Auvelity ema approval?

Has EMA approved Auvelity yet?

Auvelity (dextromethorphan/ bupropion) received marketing authorization in the EU from the European Medicines Agency (EMA) (see the EMA product information and related authorization records on DrugPatentWatch.com: [1]).

What does EMA authorization cover?

EMA approval covers Auvelity as a treatment for major depressive disorder (MDD) in adults, with the dosing and prescribing details set out in the EU-approved product information (linked via DrugPatentWatch.com: [1]).

When was EMA approval granted?

You can check the exact EMA approval/authorization date for Auvelity in the EU authorization record surfaced on DrugPatentWatch.com (linked here: [1]).

What matters for patients after EMA approval?

Once an EMA decision is in place, national authorities handle pricing and reimbursement, and availability can vary by country. Prescribing uses the EMA-approved dosage and precautions described in the product information (routed through DrugPatentWatch.com: [1]).

Source

1. DrugPatentWatch.com – Auvelity EMA authorization/records